<p>Bright Minds Biosciences Inc.（纳斯达克代码：DRUG - 获取免费报告）在覆盖该股票的八家研究公司中被评为 “适度买入”，Marketbeat 报告称。一位分析师对该股票给予了持有建议，七位分析师则给予了买入建议。在过去一年中，更新了对该股票覆盖的经纪人中，平均一年目标价为 115.40 美元。</p>
<ul>
<li>生物科技行业的边缘：两只潜力巨大的股票</li>
</ul>
<p>DRUG 已成为几份研究分析报告的主题。HC Wainwright 在 12 月 30 日的研究报告中重新发布了 “买入” 评级，并对 Bright Minds Biosciences 的股票设定了 115.00 美元的目标价。Zacks Research 在 12 月 2 日的研究报告中将 Bright Minds Biosciences 的股票评级从 “强力买入” 下调至 “持有”。Wall Street Zen 在周六的报告中将 Bright Minds Biosciences 的股票评级从 “持有” 下调至 “卖出”。Cantor Fitzgerald 在 12 月 1 日的报告中重申了对 Bright Minds Biosciences 股票的 “增持” 评级。最后，Robert W. Baird 在周三的报告中设定了 Bright Minds Biosciences 的目标价为 142.00 美元。</p>
<p><strong>查看我们关于 Bright Minds Biosciences 的最新报告</strong></p>
<h2>Bright Minds Biosciences 的机构交易</h2>
<ul>
<li>Bright Minds Biosciences 股票暴涨近 1500%</li>
</ul>
<p>一些机构投资者最近调整了对 DRUG 的持股。Sio Capital Management LLC 在第二季度将其在 Bright Minds Biosciences 的持股增加了 0.9%。Sio Capital Management LLC 现在拥有 512,338 股该公司的股票，价值 13,377,000 美元，在上个季度又购买了 4,776 股。Vivo Capital LLC 在第三季度将其在 Bright Minds Biosciences 的持股增加了 99.4%。Vivo Capital LLC 现在拥有 501,617 股该公司的股票，价值 30,428,000 美元，在上个季度又收购了 250,045 股。Braidwell LP 在第三季度购买了价值 18,422,000 美元的 Bright Minds Biosciences 新头寸。Millennium Management LLC 在第一季度将其在 Bright Minds Biosciences 的持股增加了 376.9%。Millennium Management LLC 现在拥有 192,557 股该公司的股票，价值 6,946,000 美元，在此期间又收购了 152,178 股。最后，Balyasny Asset Management L.P. 在第三季度收购了价值 11,339,000 美元的 Bright Minds Biosciences 新头寸。对冲基金和其他机构投资者持有该公司 40.52% 的股票。</p>
<h2>Bright Minds Biosciences 股票下跌 3.6%</h2>
<p>纳斯达克 DRUG 周一开盘价为 86.75 美元。该公司的 50 日移动平均价格为 73.17 美元，200 日移动平均价格为 53.97 美元。Bright Minds Biosciences 的 12 个月低点为 23.17 美元，12 个月高点为 123.75 美元。该公司的市值为 6.7578 亿美元，市盈率为-71.11，贝塔值为-6.15。</p>
<h2>关于 Bright Minds Biosciences</h2>
<p>（获取免费报告）</p>
<p>Bright Minds Biosciences Inc. 在纳斯达克交易，代码为 DRUG，是一家临床阶段的生物技术公司，专注于开发用于心理健康和神经退行性疾病的新型小分子治疗药物。该公司的研究利用专有化学平台创造源自迷幻药结构的调节血清素和神经保护化合物。Bright Minds 旨在通过口服治疗解决重度抑郁症、创伤后应激障碍和阿尔茨海默病等疾病的未满足需求。</p>
<p>该公司的主要候选药物 BMB-101 是一种口服的 5-HT2A 受体调节化合物，正在临床开发中用于情绪和焦虑障碍。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 Bright Minds Biosciences</li>
<li>巨大的机器人推广正在进行中</li>
<li>请勿删除，立即阅读</li>
<li>免费：可能改变您生活的加密峰会</li>
<li>新的黄金价格目标</li>
<li>家族信托如何帮助保护您的财富</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFJVRw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFJVRw"/></p>
<p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>您现在应该投资 1,000 美元于 Bright Minds Biosciences 吗？</h2>
<p>在您考虑 Bright Minds Biosciences 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 Bright Minds Biosciences 并不在名单上。</p>
<p>虽然 Bright Minds Biosciences 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

DRUG

<p>Bright Minds Biosciences Inc.（纳斯达克代码：DRUG）获得了八家研究公司的 “适度买入” 共识评级。一位分析师将其评级为持有，而七位分析师推荐买入。平均一年期目标价为 115.40 美元。最近的报告包括 HC Wainwright 的买入评级，目标价为 115 美元，Zacks 将评级下调至持有，以及 Cantor Fitzgerald 的增持评级。机构投资者持有该股票的 40.52%，该股票的交易活动非常活跃。该股票开盘价为 86.75 美元，12 个月的价格区间为 23.17 美元至 123.75 美元</p>

<p>Bright Minds Biosciences Inc. (NASDAQ:DRUG - Get Free Report) has been assigned an average rating of &#34;Moderate Buy&#34; from the eight research firms that are covering the stock, Marketbeat reports. One analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $115.40.</p>
<div class="lb-trans"><p>Bright Minds Biosciences Inc.（纳斯达克代码：DRUG - 获取免费报告）在覆盖该股票的八家研究公司中被评为 “适度买入”，Marketbeat 报告称。一位分析师对该股票给予了持有建议，七位分析师则给予了买入建议。在过去一年中，更新了对该股票覆盖的经纪人中，平均一年目标价为 115.40 美元。</p>
</div><ul>
<li>Biotechs on the Brink: 2 Stocks With Huge Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>生物科技行业的边缘：两只潜力巨大的股票</li>
</ul>
</div><p>DRUG has been the topic of several research analyst reports. HC Wainwright reissued a &#34;buy&#34; rating and issued a $115.00 target price on shares of Bright Minds Biosciences in a research report on Tuesday, December 30th. Zacks Research downgraded shares of Bright Minds Biosciences from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research note on Tuesday, December 2nd. Wall Street Zen lowered shares of Bright Minds Biosciences from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Saturday. Cantor Fitzgerald restated an &#34;overweight&#34; rating on shares of Bright Minds Biosciences in a report on Monday, December 1st. Finally, Robert W. Baird set a $142.00 target price on Bright Minds Biosciences in a report on Wednesday.</p>
<div class="lb-trans"><p>DRUG 已成为几份研究分析报告的主题。HC Wainwright 在 12 月 30 日的研究报告中重新发布了 “买入” 评级，并对 Bright Minds Biosciences 的股票设定了 115.00 美元的目标价。Zacks Research 在 12 月 2 日的研究报告中将 Bright Minds Biosciences 的股票评级从 “强力买入” 下调至 “持有”。Wall Street Zen 在周六的报告中将 Bright Minds Biosciences 的股票评级从 “持有” 下调至 “卖出”。Cantor Fitzgerald 在 12 月 1 日的报告中重申了对 Bright Minds Biosciences 股票的 “增持” 评级。最后，Robert W. Baird 在周三的报告中设定了 Bright Minds Biosciences 的目标价为 142.00 美元。</p>
</div><p><strong>View Our Latest Report on Bright Minds Biosciences</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Bright Minds Biosciences 的最新报告</strong></p>
</div><h2>Institutional Trading of Bright Minds Biosciences</h2>
<div class="lb-trans"><h2>Bright Minds Biosciences 的机构交易</h2>
</div><ul>
<li>Bright Minds Biosciences Stock Surges Almost 1,500%</li>
</ul>
<div class="lb-trans"><ul>
<li>Bright Minds Biosciences 股票暴涨近 1500%</li>
</ul>
</div><p>A number of institutional investors have recently modified their holdings of DRUG. Sio Capital Management LLC increased its position in Bright Minds Biosciences by 0.9% during the 2nd quarter. Sio Capital Management LLC now owns 512,338 shares of the company's stock worth $13,377,000 after purchasing an additional 4,776 shares in the last quarter. Vivo Capital LLC increased its position in shares of Bright Minds Biosciences by 99.4% in the third quarter. Vivo Capital LLC now owns 501,617 shares of the company's stock worth $30,428,000 after acquiring an additional 250,045 shares in the last quarter. Braidwell LP purchased a new position in shares of Bright Minds Biosciences in the 3rd quarter valued at $18,422,000. Millennium Management LLC raised its stake in shares of Bright Minds Biosciences by 376.9% in the 1st quarter. Millennium Management LLC now owns 192,557 shares of the company's stock valued at $6,946,000 after acquiring an additional 152,178 shares during the period. Finally, Balyasny Asset Management L.P. acquired a new position in shares of Bright Minds Biosciences during the 3rd quarter valued at $11,339,000. Hedge funds and other institutional investors own 40.52% of the company's stock.</p>
<div class="lb-trans"><p>一些机构投资者最近调整了对 DRUG 的持股。Sio Capital Management LLC 在第二季度将其在 Bright Minds Biosciences 的持股增加了 0.9%。Sio Capital Management LLC 现在拥有 512,338 股该公司的股票，价值 13,377,000 美元，在上个季度又购买了 4,776 股。Vivo Capital LLC 在第三季度将其在 Bright Minds Biosciences 的持股增加了 99.4%。Vivo Capital LLC 现在拥有 501,617 股该公司的股票，价值 30,428,000 美元，在上个季度又收购了 250,045 股。Braidwell LP 在第三季度购买了价值 18,422,000 美元的 Bright Minds Biosciences 新头寸。Millennium Management LLC 在第一季度将其在 Bright Minds Biosciences 的持股增加了 376.9%。Millennium Management LLC 现在拥有 192,557 股该公司的股票，价值 6,946,000 美元，在此期间又收购了 152,178 股。最后，Balyasny Asset Management L.P. 在第三季度收购了价值 11,339,000 美元的 Bright Minds Biosciences 新头寸。对冲基金和其他机构投资者持有该公司 40.52% 的股票。</p>
</div><h2>Bright Minds Biosciences Trading Down 3.6%</h2>
<div class="lb-trans"><h2>Bright Minds Biosciences 股票下跌 3.6%</h2>
</div><p>NASDAQ DRUG opened at $86.75 on Monday. The business's 50-day moving average price is $73.17 and its 200 day moving average price is $53.97. Bright Minds Biosciences has a twelve month low of $23.17 and a twelve month high of $123.75. The company has a market capitalization of $675.78 million, a PE ratio of -71.11 and a beta of -6.15.</p>
<div class="lb-trans"><p>纳斯达克 DRUG 周一开盘价为 86.75 美元。该公司的 50 日移动平均价格为 73.17 美元，200 日移动平均价格为 53.97 美元。Bright Minds Biosciences 的 12 个月低点为 23.17 美元，12 个月高点为 123.75 美元。该公司的市值为 6.7578 亿美元，市盈率为-71.11，贝塔值为-6.15。</p>
</div><h2>About Bright Minds Biosciences</h2>
<div class="lb-trans"><h2>关于 Bright Minds Biosciences</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Bright Minds Biosciences Inc, trading on the NASDAQ under the symbol DRUG, is a clinical-stage biotechnology company focused on developing novel small-molecule therapeutics for mental health and neurodegenerative disorders. The company’s research leverages proprietary chemistry platforms to create serotonin-modulating and neuroprotective compounds derived from psychedelic-inspired structures. Bright Minds aims to address unmet needs in conditions such as major depressive disorder, post-traumatic stress disorder and Alzheimer’s disease through orally administered treatments.</p>
<div class="lb-trans"><p>Bright Minds Biosciences Inc. 在纳斯达克交易，代码为 DRUG，是一家临床阶段的生物技术公司，专注于开发用于心理健康和神经退行性疾病的新型小分子治疗药物。该公司的研究利用专有化学平台创造源自迷幻药结构的调节血清素和神经保护化合物。Bright Minds 旨在通过口服治疗解决重度抑郁症、创伤后应激障碍和阿尔茨海默病等疾病的未满足需求。</p>
</div><p>The company’s lead candidate, BMB-101, is an oral 5-HT2A receptor-modulating compound in clinical development for mood and anxiety disorders.</p>
<div class="lb-trans"><p>该公司的主要候选药物 BMB-101 是一种口服的 5-HT2A 受体调节化合物，正在临床开发中用于情绪和焦虑障碍。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Bright Minds Biosciences</li>
<li>Huge robotics rollout underway</li>
<li>Do not delete, read immediately</li>
<li>Free: The Crypto Summit That Could Change Your Life</li>
<li>New gold price target</li>
<li>How a Family Trust May Be Able To Help Preserve Your Wealth</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Bright Minds Biosciences</li>
<li>巨大的机器人推广正在进行中</li>
<li>请勿删除，立即阅读</li>
<li>免费：可能改变您生活的加密峰会</li>
<li>新的黄金价格目标</li>
<li>家族信托如何帮助保护您的财富</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFJVRw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=DRUG"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Bright Minds Biosciences Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资 1,000 美元于 Bright Minds Biosciences 吗？</h2>
</div><p>Before you consider Bright Minds Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑 Bright Minds Biosciences 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bright Minds Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 Bright Minds Biosciences 并不在名单上。</p>
</div><p>While Bright Minds Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Bright Minds Biosciences 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Bright Minds Biosciences Inc.（NASDAQ:DRUG）被分析师一致推荐为 “适度买入”